Biomarkers are important when it comes to the development of novel drugs and mechanisms and are also gaining importance as companion diagnostic markers.
Indivumed provides extensive R&D services for biomarker assay development and clinical validation and to develop biomarkers that accurately indicate improved clinical outcomes. Our access to ischemia-controlled biospecimen as well as pathology-grade “real-life” samples shorten your time to market.
The service ranges from characterization and validation of commercial or proprietary antibodies to clinical verification and validation of the established assays. In-house pathologists create read-outs using state-of-the-art digital histopathology to provide robust results. Our biomarker analysis and development program is designed according to ISO certification, GCLP compliance, and ICH guidelines.
Indivumed serves as a partner for clinical trials, which includes both the collection of biospecimen from cancer patients as well as performing analytical assays in Indivumed’s GCLP-compliant laboratories.